CARLSBAD, Calif., Nov. 12, 2021 /PRNewswire/ -- Ionis
Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted
therapies, announced today the upcoming presentations of clinical
and non-clinical data from its cardiovascular pipeline, including
several of its investigational antisense medicines for
cardiovascular disease, at the American Heart
Association (AHA) Scientific Sessions, to be held
virtually Nov. 13-15, 2021.
New data from the Phase 1 multiple ascending dose study for
ION449 (also known as AZD8233) will be featured in an oral
presentation. ION449, an investigational antisense medicine that
uses Ionis' proprietary Ligand-Conjugated Antisense technology
(LICA), is designed to reduce the production of PCSK9 and lower the
plasma level of low-density lipoprotein-cholesterol (LDL-C) in
patients who are at risk of cardiovascular disease due to high
levels of LDL-C. Genetic studies have shown that individuals with
life-long reduction of LDL-C due to reduced function of PCSK9 have
substantially reduced risk of cardiovascular disease. Data to be
presented include results from a study evaluating the safety,
tolerability, pharmacokinetics and pharmacodynamics of multiple
ascending subcutaneous doses of ION449 in patients with
dyslipidemia. ION449 is being developed by AstraZeneca as part of a
collaboration between Ionis and AstraZeneca.
Ionis will also present data on the effect of olezarsen,
formerly known as IONIS-APOCIII-LRx, on a variety of
lipoprotein fractions measured by Nuclear Magnetic Resonance (NMR)
in patients with cardiovascular disease and hypertriglyceridemia.
The apolipoprotein C-III (apoC-III) protein is an independent
cardiovascular risk factor that regulates triglyceride metabolism
in the blood. Olezarsen is designed to inhibit the production of
apoC-III in patients who are at risk for cardiovascular disease due
to elevated triglyceride levels. Olezarsen is an investigational
antisense medicine that was also developed using Ionis'
advanced LICA technology. Olezarsen is currently being
evaluated in two phase 3 clinical studies as part of Ionis' broad
development program. The CORE study is evaluating olezarsen's
potential to treat diseases caused by severe hypertriglyceridemia.
BALANCE is a study evaluating olezarsen in people with familial
chylomicronemia syndrome or FCS.
In addition, Ionis will host a sponsored symposium, "Hidden in
Plain Sight: ATTR-CM in Overlooked Patient Populations" to discuss
the prevalence of cardiomyopathy in Blacks and African Americans
while addressing biological and genetic differences.
The following is a schedule of the events and presentations of
Ionis programs and collaborations.
Saturday, Nov. 13, 8:00- 5:30 AM ET (on demand)
Scientific
Session: Unraveling Dyslipidemias: Learning from Basic Science to
Improve Treatment. Sotirios "Sam" Tsimikas, M.D., senior vice
president and franchise leader of cardiovascular programs at Ionis,
who specializes in lipoprotein(a), will present "Basic Science
Evidence Based Approaches to Lp(a) Disorders." Lp(a) is a
lipoprotein particle assembled in the liver that consists of an
LDL-C-like particle and apolipoprotein(a). Lp(a) is considered a
key driver for cardiovascular disease due to its association with
an increased risk of coronary heart disease. This educational
session was planned by the Committee on Scientific Sessions Program
and aims to cover the "best of 2020" cutting edge research that
have advanced cardiovascular science and approaches to
treatment.
Sunday, Nov.14, 7:30-9:00 p.m.
ET
Symposium: Hidden in Plain Sight: ATTR-CM in
Overlooked Patient Populations
Transthyretin amyloid cardiomyopathy, or ATTR-CM, is a serious
and underdiagnosed type of amyloidosis that primarily affects the
heart and leads to heart failure. Ionis will host a symposium
focused on the prevalence of ATTR-CM in Blacks and African
Americans and in subpopulations with heart failure with preserved
ejection fraction (HFpEF), addressing biological and genetically
inherited differences, implicit bias, and healthcare challenges
that may disproportionately impact the diagnosis and treatment of
those groups. Panel includes Dr. Mathew
Maurer, Columbia University;
Dr. Alanna Morris, Emory
University; Dr. Kevin
Alexander, Stanford University;
and Dr. Keyur Shah, Virginia Commonwealth University.
The following are presentations that will be available on the
AHA Scientific Sessions' website.
Saturday, Nov. 13, 2021,
8:00 AM - 5:30 PM
Safety,
pharmacokinetics and pharmacodynamics of multiple ascending doses
of AZD8233 targeting PCSK9, in patients with dyslipidemia (Oral
presentation 268)
FAT's What It's All About! Lipid, Lipid Lowering Agents and PCI
Saturday, Nov. 13, 2021,
8:00 AM - 5:30 PM (ePoster
VMP33)
Effect of olezarsen on lipoprotein size and particle numbers
measured by NMR in patients with hypertriglyceridemia: Results of
the olezarsen trial
New Mechanisms and Therapeutic Developments in Lipid Metabolism
Saturday, Nov. 13, 2021,
8:00-5:30 PM (on
demand)
George Lyman Duff
Memorial Lecture: Interventional Hepatic ApoC-III Knockdown
Improves Atherosclerotic Plaque Stability and Remodeling via
Lowering Remnant Lipoproteins
Saturday, Nov. 13, 2021,
2:30-3:30 PM (ePoster P1104)
Relationship Between Circulating Levels of Angiotensinogen and
Hypertension—The Multi-Ethnic Study of Atherosclerosis
Saturday, Nov. 13, 2021,
11:00 AM - 12:00 PM (ePoster
P108/1006)
Total lipoprotein lipase deficiency does not impact atherosclerosis
development in low density lipoprotein receptor deficient mice
Lipids and Lipoproteins in Atherosclerosis
Embargoed abstracts and details on presentation times and dates
can be found on the AHA 2021 Scientific Session Online Program
Planner.
About Ionis Pharmaceuticals, Inc.
For more than 30 years, Ionis has been the leader in
RNA-targeted therapy, pioneering new markets and changing standards
of care with its novel antisense technology. Ionis currently has
three marketed medicines and a premier late-stage pipeline
highlighted by industry-leading neurological and cardiometabolic
franchises. Our scientific innovation began and continues with the
knowledge that sick people depend on us, which fuels our vision of
becoming one of the most successful biotechnology companies.
To learn more about Ionis,
visit www.ionispharma.com and follow us on twitter
@ionispharma.
Ionis' Forward-looking Statement
This press release includes forward-looking statements regarding
Ionis' business, and the therapeutic and commercial potential of
Ionis' technologies, ION449, olezarsen and other products in
development. Any statement describing Ionis' goals, expectations,
financial or other projections, intentions or beliefs is a
forward-looking statement and should be considered an at-risk
statement. Such statements are subject to certain risks and
uncertainties, including those related to the impact COVID-19 could
have on our business, and including but not limited to those
related to our commercial products and the medicines in our
pipeline, and particularly those inherent in the process of
discovering, developing and commercializing medicines that are safe
and effective for use as human therapeutics, and in the endeavor of
building a business around such medicines. Ionis' forward-looking
statements also involve assumptions that, if they never materialize
or prove correct, could cause its results to differ materially from
those expressed or implied by such forward-looking statements.
Although Ionis' forward-looking statements reflect the good
faith judgment of its management, these statements are based only
on facts and factors currently known by Ionis. As a result, you are
cautioned not to rely on these forward-looking statements. These
and other risks concerning Ionis' programs are described in
additional detail in Ionis' annual report on Form 10-K for the year
ended December 31, 2020, and the most recent Form 10-Q
quarterly filing, which are on file with the SEC. Copies of
these and other documents are available from the Company.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ionis-antisense-therapies-to-be-featured-at-the-american-heart-association-aha-scientific-sessions-2021-301422831.html
SOURCE Ionis Pharmaceuticals, Inc.